Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

2.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.

3.

Oncology Drug Shortages Persist, but Continue to Evolve

4.

Is Exercise an Effective Treatment for Prostate Cancer?

5.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot